戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1      Time to diagnosis of AF was the primary outcome measure.
2 sions reduced loss adaptation in the primary outcome measure.
3 on with total volume of distribution (VT) as outcome measure.
4 ation of microglial activation as an imaging outcome measure.
5 e presence or absence of SCT was the primary outcome measure.
6 ucleatum were analyzed for prediction of the outcome measure.
7 xycholesterol levels in serum as the primary outcome measure.
8 observed treatment effects on any behavioral outcome measure.
9 re used to analyze the longitudinal repeated outcome measures.
10 h the clinician-administered and self-report outcome measures.
11 created to estimate odds ratios for the main outcome measures.
12 mory, and processing speed) were the primary outcome measures.
13 ects of levothyroxine were seen on secondary-outcome measures.
14  (n = 10) reported no significant changes in outcome measures.
15 amplitude change predicted post-hoc learning outcome measures.
16 ly important differences (MID) were the main outcome measures.
17 results, as measured by objective functional outcome measures.
18 e found similar results in several secondary outcome measures.
19 an difference 0.006, -0.009 to 0.02; p=0.42) outcome measures.
20 , and health-related quality-of-life (HRQoL) outcome measures.
21 disease and vascular dementia were secondary outcome measures.
22 ysical and mental health, medication and BMI outcome measures.
23 del) maximized performance across a range of outcome measures.
24         Four criteria are proposed to assess outcome measures.
25 GD) and correlate these data with functional outcome measures.
26 SF can provide greater precision than scalar outcome measures.
27 spectral domain optical coherence tomography outcomes measured.
28 etest control that did not complete the main outcome measures; 16 participants provided no state-chan
29 of questionnaires as patient/person-reported outcome measures; 3) describe prescribed medications, or
30 ild development is related to adult economic outcomes measured 30 y later.
31         Of interest, although not defined as outcome measures a priori, the KGF group, compared with
32 bidity, which has meanwhile reached standard outcome measures accepted for major liver surgery.
33 t tests were used to identify differences in outcome measures after the institution of reforms.
34                                  The primary outcome, measured after listening to the entire podcast,
35  25 mm Hg in both studies (ROCKET-2, primary outcome measure and population, ROCKET-1, post hoc outco
36 ical activity, heterogeneity between dietary outcome measures and a paucity of evidence around harmfu
37 ty instruments, including patient-orientated outcome measures and objective signs (Eczema Area and Se
38    At month 6, 348 participants (96%) had VA outcomes measured and 335 participants (93%) had spectra
39     Incident all-cause dementia was the main outcome measure, and single- and dual-task gait velocity
40 dy characteristics, patients, interventions, outcome measures, and results at short- and long-term fo
41 is (CF) indicates that sensitive noninvasive outcome measures are needed for diagnostic monitoring an
42                             Patient-reported outcome measures are problematic, because low response r
43                               Primary safety outcome measures are the incidence of study product-rela
44 each statistical significance for predicting outcome measured as a continuous variable (p = 0.07) for
45     Primary end points were patient-reported outcome measures as assessed by the validated BREAST-Q s
46       Morbidity rate has become an important outcome measure, as the mortality rates of most surgical
47                                         Main outcome measures assessed every 6 mo included the total-
48  were administered the A-IQOLS, other asthma outcome measures (Asthma Control Test, Asthma Symptom Ut
49                           The main secondary outcome measure at 1 year follow-up was disability, meas
50 f 779 patients provided data for the primary outcome measure at baseline and at least 1 follow-up.
51 baseline and every 4 weeks, with the primary outcome measured at 6 months.
52 y of maternal-infant attachment was the main outcome measured at infant age 18 mo.
53  3 days post injury strongly correlates with outcome measures at 12 weeks post injury.
54 ipants enrolled, 139 (94%) completed primary outcome measures at 3 months and 133 (90%) completed sec
55                                              Outcome measures at 3 months, 6 months, and 9 months pos
56 between self-harm during adolescence and the outcome measures at 35 years (wave 10) using logistic re
57 t 3 months and 133 (90%) completed secondary outcome measures at 9 months; multiple imputation was us
58                                          The outcome measures at age 35 years were social disadvantag
59 s for 2 years after the surgery; the primary outcomes, measured at 1 year and 2 years, were participa
60 he identification of potential biomarkers of outcome measures, availability of relevant animal models
61                                              Outcome Measures: Average lifetime costs, life-years, an
62 gnosed at younger than 20 years, with single outcome measures between 2011 and 2015.
63 ns were found between MMI score and practice outcomes measured by mentor grading.
64                                   Functional outcomes measured by the absolute value and the variatio
65 te significant heterogeneity in exposure and outcome measures, clear evidence shows that the burden o
66 and CHALICE in predicting each rule-specific outcome measure (clinically important traumatic brain in
67  the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM), with higher scores indicating
68 d for a national dialogue about how to judge outcome measures currently in use or proposed for the fu
69            These criteria were applied to 10 outcome measures currently used or proposed for accounta
70 art of treatment to "presumed cure" (primary outcome measure, defined as a closed epithelial defect w
71                                              Outcome measures defining the impact of globalization on
72 NTERPRETATION: These data of SMA and control outcome measures delineates meaningful change in clinica
73  function was found to be a suitable primary outcome measure for a future trial; adjusted mean differ
74 clinical evaluation and has usefulness as an outcome measure for future retinal intervention studies.
75 g 1 year, BCVA is unlikely to be a sensitive outcome measure for STGD1 treatment trials with 1 year's
76 estigation of disease pathogenesis and as an outcome measure for therapeutic interventions.
77 ing that incidence of DDAF could serve as an outcome measure for treatment trials.
78                                 To determine outcome measures for a clinical trial of Leber congenita
79  These variables would be potential anatomic outcome measures for CHM clinical trials and could be st
80 ay help outline the eligibility criteria and outcome measures for clinical trials for CHM.
81                                    Sensitive outcome measures for clinical trials on cerebellar ataxi
82                                     Our main outcome measures for comparison between groups were (1)
83                                    Sensitive outcome measures for disease progression are needed for
84                       A comprehensive set of outcome measures for liver diseases is not currently ava
85 ich to date have relied solely on functional outcome measures for patient enrollment, stratification,
86                   No difference was found in outcome measures for patients with AF and age- and sex-m
87  of overlapping phenotypes that may serve as outcome measures for preclinical studies of PTHS treatme
88  hospital and ICU lengths of stay (LOS) were outcome measures for severity.
89                                  The primary outcome measures for the study were coverage of OPV, IPV
90 nt next step toward developing a set of core outcome measures for this field of research.
91                                          New outcome measures for treatment trials for Stargardt dise
92                                              Outcome Measures: HIV transmissions and deaths, years of
93 ve and positive biopsies were similar in the outcome measures; however, positive-biopsy patients were
94    Survival analysis represents an important outcome measure in clinical research and clinical trials
95   This could be used as a sensitive anatomic outcome measure in clinical trials related to STGD.
96 of retinal function and will be an important outcome measure in future clinical trials.
97 tions in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) cohort, we an
98 nts from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) using questio
99 e SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) cohort.
100 aled stronger positive associations for most outcome measures in males and at doses below the current
101                                          The Outcome Measures in Rheumatology comprehensive conceptua
102 g emphasis on incorporating patient-reported outcome measures in routine care for patients with heart
103 s to identify and delineate relevant patient outcomes measured in studies that reported nursing inter
104 e SPIROMICS (Subpopulations and Intermediate Outcomes Measures in COPD Study) (n = 1,544) and COPDGen
105                                    Secondary outcome measures include IOP, glaucoma medical therapy,
106                                         Main outcome measures include proportion of eye care provider
107                                    Secondary outcome measures included 30-day postoperative complicat
108                                              Outcome measures included AL, corneal curvature, and the
109                                              Outcome measures included C. difficile test utilization,
110                                      Primary outcome measures included change in proteinuria and chan
111                                    Secondary outcome measures included changes in pulse wave velocity
112  calibrated and blinded examiners; secondary outcome measures included decayed, missing, or filled te
113                                              Outcome measures included densitometry data in 4 corneal
114                                          Our outcome measures included differences in RNFL thickness
115            Additional prespecified secondary outcome measures included health-related quality of life
116                                         Main outcome measures included incidence rates of vision loss
117                                    Secondary outcome measures included induction of labor, low birth
118                                 Prespecified outcome measures included low-grade CIN (grade 1 [CIN1])
119                                    Secondary outcome measures included mean change in visual acuity (
120                                         Main outcome measures included participant's decision to acce
121                                         Main outcome measures included rates of visual loss and ocula
122                                              Outcome measures included reduction in intraocular press
123                                         Main outcome measures included safety (rate of treatment-rela
124                                              Outcome measures included scores on neuropsychological m
125                                         Main outcome measures included serious morbidity, in-hospital
126                                    Secondary outcome measures included surgical feasibility, visual a
127                                    Secondary outcome measures included the number of charges submitte
128                             Patient-reported outcome measures included the scores on the Physical Com
129                                    Secondary outcome measures included the time until onset of pain a
130                                    Secondary outcome measures included time to tumor progression, pro
131                                              Outcome measures included total distance traveled and ra
132                                              Outcome Measures: Incremental costs, quality-adjusted li
133 riance in cognitive performance and clinical outcome measures, independent of the associated antecede
134 riance in cognitive performance and clinical outcome measures, independently and jointly.
135 of improvement in study design, selection of outcome measures, interpretation of results, and the ove
136                                         Main outcome measure is consistency of ophthalmic outcomes me
137                                  The primary outcome measure is the rate of surgical failure, defined
138 et longitudinally collected patient-reported outcome measures is unknown.
139 omography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic functio
140                                              OUTCOME MEASURES: lowest observed adverse effect levels
141                An additional 56 prespecified outcomes measured maternal health-care use, content of c
142                                              OUTCOME MEASURES: MNRead maximum reading speed, sustaine
143                Fourth, implementation of the outcome measure must have little chance of inducing unin
144  were identified comprising patient reported outcome measures (n=31), and biologic measures and repor
145                                              OUTCOME MEASURE: Odds ratios (OR) were calculated for gl
146      INTERPRETATION: Using the CMTPedS as an outcome measure of disease severity, children with CMT p
147 ripheral biomarker candidate as an objective outcome measure of target engagement for clinical trials
148                                              Outcome measures of brain metabolism, neuroinflammation,
149 ween lanicemine and placebo treatment on any outcome measures related to MDD.
150  observe significant differences in multiple outcome measures related to the affective sphere of pain
151 tically significant improvements on multiple outcome measures related to the affective sphere of pain
152                            We also extracted outcome measures relevant to DR and asked respondents to
153 outcome measure is consistency of ophthalmic outcomes measures reported.
154 nd secondary endpoints, and patient-reported outcome measures, reported in the methods and results se
155                                         MAIN OUTCOME MEASURE(S): At 3 months postoperatively, UCVA an
156                                           An outcome measure should be used only if the outcome can b
157  Hence, there is a strong need for sensitive outcome measures such as disease and progression biomark
158  similar effects on several of the secondary outcome measures, such as the PANSS negative symptom, to
159 nagement decisions, the absence of a uniform outcome measure that represents visual or aesthetic sequ
160                                              Outcome measures that are sensitive to disease progressi
161 ied, and reported, a set of multidimensional outcome measures that are sensitive to nursing intervent
162 ific HRQoL instruments because there are few outcome measures that are validated and reliable in pati
163                                              Outcome measures that reflect the entire cycle of care a
164 nce from placebo was detected on the primary outcome measure, the parent-rated Aberrant Behavior Chec
165                                         MAIN OUTCOMES MEASURES: The primary objective was to show non
166  found no effect of simvastatin on the other outcome measures, these potential effects warrant confir
167                         We present a list of outcome measures to enable the pooling and comparison of
168 ibing the natural history, and ultimately as outcome measures to evaluate therapies.
169       A standardized set of patient-centered outcome measures to inform value-based health care in co
170                                      PRIMARY OUTCOME MEASURE: Uncorrected (UCDVA) and best-corrected
171                                      Primary outcome measures varied across the trials analysed: two
172                                              Outcome measures varied from study to study and included
173 nge from baseline to month 24 on the primary outcome measure was 0.18 for olesoxime and -1.82 for pla
174                                  The primary outcome measure was 30-day ERI.
175                                  The primary outcome measure was 5-year overall survival.
176                                  The primary outcome measure was a three-level outcome - survival wit
177                                  The primary outcome measure was all-cause mortality rate at 2 weeks
178                                  The primary outcome measure was all-cause mortality within 30 days o
179                                  The primary outcome measure was all-cause mortality.
180                                  The primary outcome measure was anterior chamber cell grades at day
181                                     Our main outcome measure was change from month 6 to month 12 in v
182                                     The main outcome measure was change in amblyopic eye VA from base
183                                  The primary outcome measure was change in antimicrobial prescription
184                                  The primary outcome measure was change in BMI over 5 years.
185                                     The main outcome measure was change in infection rates from basel
186                                  The primary outcome measure was change in score on the Montgomery-As
187                                  The primary outcome measure was change in sickness absence among tho
188                                  The primary outcome measure was child weight loss (body mass index [
189                                  The primary outcome measure was clinical event rates, measured from
190                                  The primary outcome measure was conversion from caries-free to carie
191                                  The primary outcome measure was conversion from caries-free to carie
192 on revascularisation) and the primary safety outcome measure was definite or probable device thrombos
193                                  The primary outcome measure was development of >/=1 SAE; secondary o
194                                  The primary outcome measure was device retention at 24 and 60 months
195                                         Main outcome measure was final anatomic status.
196                                     Our main outcome measure was fractional anisotropy (FA), a measur
197                                      Primary outcome measure was hazard ratio (HR) of failure, with f
198                                          The outcome measure was improvement in probing depth of >/=2
199                                  The primary outcome measure was in-hospital mortality.
200                                     The main outcome measure was in-hospital mortality.
201                                      Primary outcome measure was incidence and severity of systemic a
202                                      Primary outcome measure was intraocular pressure (IOP) reduction
203                                  The primary outcome measure was late toxicity.
204                                  The primary outcome measure was methyl aminolevulinate-induced PPIX
205                                  The primary outcome measure was net health benefit (NHB), which was
206                                  The primary outcome measure was overall survival (defined as the dif
207                                  The primary outcome measure was overall survival, and primary and sa
208                                  The primary outcome measure was overall survival.
209                                  The primary outcome measure was overall survival; short-term periope
210                                     The main outcome measure was prediction error at 7 years of age.
211                                     The main outcome measure was SLT success (defined as IOP </= targ
212                                  The primary outcome measure was speech comprehension score on the co
213                                  The primary outcome measure was SSI score 24 hours after infusion (a
214                                  The primary outcome measure was the Alzheimer's Disease Cooperative
215                                         Main outcome measure was the annual incidence and prevalence
216                                  The primary outcome measure was the area under the curve (AUC) of cu
217                                          The outcome measure was the binding potential (BPND), using
218                                  The primary outcome measure was the change in 6-minute walk distance
219                                  The primary outcome measure was the change in the 17-item Hamilton D
220                                  The primary outcome measure was the change in the Epworth Sleepiness
221                                  The primary outcome measure was the change in the preoperative visua
222                                          The outcome measure was the concordance between the percenta
223                         The primary efficacy outcome measure was the device-oriented composite endpoi
224                                     The main outcome measure was the diagnosis of macular edema withi
225                                      Primary outcome measure was the difference in change in central-
226      Based on a previous report, the primary outcome measure was the effect of intra-epoch time (i.e.
227                                  A secondary outcome measure was the effect of the site of the primar
228                                  The primary outcome measure was the frequency of AEs.
229                                The secondary outcome measure was the impact of postoperative prophyla
230                                  The primary outcome measure was the negative predictive value (NPV)
231                                     The main outcome measure was the odds of discharge within 6 hours
232                                  The primary outcome measure was the PANSS negative factor score (pen
233                                  The primary outcome measure was the percentage of families stopping
234                                      Primary outcome measure was the proportion of patients with a st
235                                  The primary outcome measure was the rate of recurrent biliary events
236                                         Main outcome measure was the retention of the capsular bag.
237                                  The primary outcome measure was the shift in the degree of disabilit
238                                  The primary outcome measure was the shift in the degree of disabilit
239                                  The primary outcome measure was to characterize the clinical feature
240                                     The main outcome measure was vision-related functional burden, wh
241                                          The outcome measure was VT/fP (VT is volume of distribution
242                                  The primary outcome measured was the postoperative early and late co
243 e measure and population, ROCKET-1, post hoc outcome measure). was also noninferior to timolol (ROCKE
244 nitive impairment or dementia) at 2 years as outcome measures, we assessed the predictive values of b
245                                        Other outcome measures were also not different between groups.
246                                         Main outcome measures were asthma-related hospitalizations (6
247                                              Outcome measures were audibility, scores from the speech
248                                     The main outcome measures were baseline NEI VFQ-25 composite and
249                                     Our main outcome measures were best spectacle-corrected visual ac
250                          Finally, simplified outcome measures were calculated as ratio, with referenc
251                                         Main outcome measures were changes from central gaze in the c
252                                  The primary outcome measures were clinicopathological characteristic
253                                        Other outcome measures were corrected distance visual acuity (
254 asure was development of >/=1 SAE; secondary outcome measures were death, arteriothrombotic events, e
255                                  The primary outcome measures were depression (measured by the PHQ-2
256                                     The main outcome measures were diabetes (fasting plasma glucose >
257                                  The primary outcome measures were diagnostic accuracy, sensitivity,
258                        Two composite primary outcome measures were evaluated: (i) CVD events/deaths (
259                                  The primary outcome measures were for insomnia, paranoia, and halluc
260                                    Secondary outcome measures were functional outcome, health-related
261                                         Main outcome measures were hazard ratios (HRs) for post-surge
262                                              Outcome measures were implant and FPD failures, biologic
263                                              Outcome measures were improvement of discrimination by a
264                                     The main outcome measures were incidence of graft infection, micr
265                                         Main outcome measures were incidence or progression of DME or
266                                              Outcome measures were incremental cost-effectiveness rat
267                                  The primary outcome measures were IOP reduction and the success rate
268                                  The primary outcome measures were levels of plasma metabolites in pa
269                                      Primary outcome measures were mean change in (1) tear osmolarity
270                                         Main outcome measures were mean IAIs given through month 12 (
271                                     The main outcome measures were mortality and unfavourable functio
272                                    Secondary outcome measures were number of decayed, missing, or fil
273 ents, the CMT neuropathy score and secondary outcome measures were obtained and a skin biopsy collect
274                                  The primary outcome measures were overall mortality and cancer-speci
275                                    Secondary outcome measures were PANSS total score and scores on th
276                                              Outcome measures were plaque index (PI), gingival index
277                                  The primary outcome measures were positive donor rim fungal culture
278                                     The main outcome measures were postoperative best-corrected visua
279                                     The main outcome measures were postoperative surgical outcomes an
280                                    Secondary outcome measures were PPIX photobleaching and clinical l
281                                     The main outcome measures were risk of postpartum AD, duration of
282                                         Main outcome measures were spending by Medicare as tracked by
283                                  The primary outcome measures were the Evaluation du Vecu de l'Anesth
284                                         Main outcome measures were the incidence of elevated IOP and
285                                         Main outcome measures were the incidences of HIT-specific com
286                                      Primary outcome measures were the mean and median CMS payments t
287                                              Outcome measures were the observed rate of corneal chang
288                                  The primary outcome measures were the postintervention changes in fu
289                                      Primary outcome measures were the prevalence of diagnosed ocular
290                                     The main outcome measures were the proportion of children develop
291                                      Primary outcome measures were the Rating for Premenstrual Tensio
292                                  The primary outcome measures were the suicide items from clinician-a
293                                         Main outcome measures were time to distant failure, local fai
294                                              Outcome measures were type I collagen crosslinked beta C
295                                     The main outcome measures were: total number of drops, volume per
296                                          The outcomes measured were health-care costs accrued in the
297 udies (n = 36) reported one or more positive outcome measures, whereas 22% of studies (n = 10) report
298  autoregulation index that predicted patient outcome measured with the Glasgow Outcome Scale as a con
299 ete disability]) at 6 months was the primary outcome measure, with a minimal clinically important dif
300 h FC, PPT was more effective than SMC on all outcomes measured, with the exception of findings from t

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top